<div data-server-rendered="true" id="__nuxt"><div id="__layout"><div class="outer-container"><div class="content-container"> <div class="answer_container" style="min-height:calc(100vh - 54px);" data-v-0eba195e=""><div class="content_outer_container" data-v-0eba195e=""><div class="share_preview_container" data-v-0eba195e=""><div class="dialog_list" data-v-0eba195e=""><div class="dialog_item" data-v-0eba195e=""><div class="dialog_question fir_dialog_question" data-v-0eba195e=""><div class="question_con" data-v-0eba195e=""><h1 class="fir_question_content" data-v-0eba195e="">
                                    What caused ENTA's Q4 2024 EPS to fall below forecasts?
                                </h1> <div class="user_slot" data-v-0eba195e=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/default_aime_user.ec532c9.png" alt="user" class="avatar" data-v-0eba195e=""> <span class="user_desction" data-v-0eba195e="">
                                        
                                        4/6/2025 12:39am
                                    </span></div></div></div> <div class="seo-text-answer" data-v-0eba195e="">Enanta Pharmaceuticals' Q4 2024 EPS fell below forecasts due to several factors:

1. **Revenue Miss**: Enanta reported a revenue of $14.6 million for Q4 2024, which missed the estimates. This decline in revenue could contribute to the lower-than-expected EPS.
2. **Increased Losses**: The company reported a net loss of $28.8 million for the quarter, which translates to a loss of $1.36 per share. This indicates a significant financial strain that could impact the EPS negatively.
3. **Non-Recurring Items**: The quarterly report adjustments for non-recurring items suggest that there may have been one-time expenses or deductions that affected the net income and, consequently, the EPS.

In summary, Enanta's Q4 2024 EPS fell below forecasts due to a combination of revenue missing expectations, increased losses, and the impact of non-recurring items.</div> <div class="dialog_answer" data-v-0eba195e=""><div class="dialog_content" data-v-0eba195e=""><div class="answer_content" data-v-0eba195e=""></div></div></div></div></div> </div></div></div> </div> <div class="extra-module" data-v-261d488f=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/recommend-logo.4f9ccc8.png" alt="right-logo" fetchpriority="high" class="recommend-logo-img" data-v-261d488f=""> <div class="recommend-part" data-v-7790c618="" data-v-261d488f=""><div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/screener-recommend-icon.b007ca8.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime finds your next big stock</span></div> </div> <div class="recommend-query-card" data-v-8359219a="" data-v-7790c618=""><div class="title" data-v-8359219a=""><img src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/img/stock-recommend-icon.77f1c78.svg" alt="icon" data-v-8359219a=""> <span data-v-8359219a="">Aime powers your decisions</span></div> </div></div> </div> <div class="container-mask" style="display:none;"></div></div></div></div><script>window.__NUXT__=(function(a,b,c,d,e,f,g,h,i,j,k,l,m,n,o,p,q,r,s,t,u,v,w,x,y,z,A,B,C,D,E,F,G,H,I,J,K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y,Z,_,$,aa,ab,ac,ad,ae,af,ag,ah,ai,aj,ak,al,am,an,ao,ap,aq,ar,as,at,au,av,aw,ax,ay,az,aA,aB){return {layout:"default",data:[{noData:c,currentQuestion:h,textDescription:J,comeFrom:"AInvestShareLink",events:[],answerSource:n}],fetch:{},error:o,state:{sharePreviewModule:{loadJgySuccess:k,dialogRenderList:[{originAnswer:{input_media_info:[],session_round:1,agent_id:a,output_media_info:[],task_id:a,language:a,source:n,cache_builder:a,reply_action:"Answer",execute_mode:C,event_refresh_answer:a,param:"{\"entity_info\":{},\"add_info\":{\"ori_question\":\"What caused ENTA's Q4 2024 EPS to fall below forecasts?\"},\"event_list\":[],\"client_ip\":\"\",\"question\":\"What caused ENTA's Q4 2024 EPS to fall below forecasts?\",\"user_id\":\"dp22430709\",\"user_name\":\"\",\"trace_id\":\"b04f86f8-c95b-411d-b349-4424c2fc07b7\",\"session_id\":\"b04f86f8-c95b-411d-b349-4424c2fc07b7\",\"source\":\"ths_ainvest_lite_web\",\"input_type\":\"typewrite\"}",agent_info:[{info_type:K,raw_data:{number:L,title:M,summary:N,full_summary:a,url:O,image_url:a,video_url:a,publish_time:P,search_extra_info:{search_burial_info:{id:Q,uid:D,ab:{scene_id:w,layer_exp:[{layer_id:x,exp_id:y}]}}},simhash:"8ec4337eb15640b",msg_id:D}},{info_type:K,raw_data:{number:R,title:S,summary:T,full_summary:a,url:U,image_url:a,video_url:a,publish_time:V,search_extra_info:{search_burial_info:{id:W,uid:E,ab:{scene_id:w,layer_exp:[{layer_id:x,exp_id:y}]}}},simhash:"37db4d5f2bf52787",msg_id:E}}],answer_chain_name:X,agent_mode:Y,native_answer:a,come_from:a,text_answer:J,trace_id:i,cost:24618,event_names:a,question:h,fallback_type:Z,input_type:_,fall_back_reason:{fall_back_type:Z,risk_detail:{matched_words:[]}},session_id:i,first_return_cost:3980,cache_type:a,question_id:i,transfer_question:h,signal_type:"ON_COMPLETE",start_time:$,remote_svc:n,slots:[],answer_type:C,user_id:z,skill_name:F},renderList:[{type:"base_info",answer_path:"logs\u002FbaseInfo",logs:[],base_info:{trace_id:i,session_id:i,user_id:z,question:h,source:n,raw_question:h,version:"3.4.1",action_name:F,nlu:{entity:[{type:aa,value:"ENTA.O",market:ab}]},deep_research:c,deep_thinking:c,agent_mode:Y},extra:{}},{answer_path:d,section:{id:e,info_texts:["Thinking"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"begin"},logs:[],extra:{is_deep_research:c,deep_thinking:c}},{answer_path:d,section:{id:e,info_texts:["Querying Stock: ENTA Latest Report Period"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:ac,action_input:"ENTA Latest Report Period",thought:p}},{answer_path:d,section:{id:e,info_texts:["Querying Stock: ENTA Earnings Release Date"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:ac,action_input:"ENTA Earnings Release Date",thought:p}},{answer_path:d,section:{id:e,info_texts:["Searching Web: Enanta Pharmaceuticals Analyst Consensus Rating"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:q,action_input:"Enanta Pharmaceuticals Analyst Consensus Rating",thought:p}},{answer_path:d,section:{id:e,info_texts:["Searching Web: Enanta Pharmaceuticals Analyst Opinions"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:q,action_input:"Enanta Pharmaceuticals Analyst Opinions",thought:p}},{answer_path:d,section:{id:e,info_texts:["Searching Web: Why Enanta Pharmaceuticals Missed Expectations"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:q,action_input:"Why Enanta Pharmaceuticals Missed Expectations",thought:p}},{answer_path:g,section:{id:G,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:e,info_texts:["Searching Web: Enanta Pharmaceuticals Revenue Analysis"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:q,action_input:"Enanta Pharmaceuticals Revenue Analysis",thought:ad}},{answer_path:d,section:{id:e,info_texts:["Searching Web: Enanta Pharmaceuticals Statutory Loss Per Share Analysis"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:j},logs:[],extra:{action:q,action_input:"Enanta Pharmaceuticals Statutory Loss Per Share Analysis",thought:ad}},{answer_path:g,section:{id:G,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:G,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:d,section:{id:e,info_texts:["Generating Answer"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"ongoing"},logs:[],extra:{}},{answer_path:g,section:{id:r,info_texts:[],show_type:l,voice_txt:"En",text_answer:ae,rich_text:ae,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:1001,info_texts:[],show_type:"fenshi",choice:[],result_page:{},tag_info_list:[{stock_info:{code:"ENTA",market_id:ab,name:af,domain:aa},pos:k,section_id:r,txt:af,jump_type:"pos_fenshi"}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:r,info_texts:[],show_type:l,voice_txt:".",text_answer:ag,rich_text:ag,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:ah,info_texts:[],show_type:l,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:O,image_url:a,video_url:a,title:M,summary:N,index:L,publish_time:P,search_id:Q,search_uid:D,search_ab:{scene_id:w,layer_exp:[{layer_id:x,exp_id:y}]},jump_type:ai}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:r,info_texts:[],show_type:l,voice_txt:". This",text_answer:aj,rich_text:aj,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:ah,info_texts:[],show_type:l,voice_txt:a,text_answer:a,rich_text:a,choice:[],result_page:{},tag_info_list:[{url:U,image_url:a,video_url:a,title:S,summary:T,index:R,publish_time:V,search_id:W,search_uid:E,search_ab:{scene_id:w,layer_exp:[{layer_id:x,exp_id:y}]},jump_type:ai}],is_last:b},logs:[],extra:{}},{answer_path:g,section:{id:r,info_texts:[],show_type:l,voice_txt:".\n\nIn",text_answer:ak,rich_text:ak,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"extraInfo\u002FsourceLink",logs:[],extra:{span_id:a,link_id:a,source:a,link_text:a,link_param:a,link_ids:[]}},{answer_path:d,section:{id:e,info_texts:["Completed"],show_type:f,choice:[],result_page:{},tag_info_list:[],is_last:b,status:"end"},logs:[],extra:{}},{answer_path:"suggest\u002Fquestions",section:{id:10002,info_texts:[],show_type:"result_page",choice:[{display_text:s,query_text:s,trace_info:{item_id:"54888ad23cc76ba265337f5b37c04dd5",item_type:m,item_name:s,rec_info:al}},{display_text:t,query_text:t,trace_info:{item_id:"4a78a47284bd7b427966838edc12319b",item_type:m,item_name:t,rec_info:am}},{display_text:u,query_text:u,trace_info:{item_id:"20e41621b0f612e0a5fc92de9caab015",item_type:m,item_name:u,rec_info:an}}],result_page:{components:[{show_type:"lowcode",title_config:{show_type:"title1",data:{h1:a,h2:a},config:{display:c,txt_style:k,type:"1",display2:c,url:a}},request_config:[{source_type:ao,related_name:ap}],puuid:H,tag:a,category:"custom",uuid:aq}],global:{urp_static_data:[{name:ap,value:{status_code:k,columns:[{type:v,index_name:ar,key:ar},{type:v,index_name:as,key:as},{type:v,index_name:at,key:at},{type:v,index_name:au,key:au},{type:v,index_name:av,key:av}],datas:[{send_text:s,item_type:m,rec_info:al,display_text:s,rec_reason:a},{send_text:t,item_type:m,rec_info:am,display_text:t,rec_reason:a},{send_text:u,item_type:m,rec_info:an,display_text:u,rec_reason:a}],dataSize:ao,status_msg:a}}],lowcode_type:"shunda",interface_request_list:[],lowcode_json:{stack:c,visible:b,childLimit:9999,label:aw,type:"thslc\u002Fthslc-common-container",leaf:c,animate:[],version:"1.0.1",script:[],props:[],path:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fkernel-thslc-resource\u002Fresource\u002Fainvest\u002F0Ae514cfA4\u002Fjs\u002F_thslc-common-container_1.0.1_index.js",isTransparent:b,style:{"background-color":a,"box-shadow":"0px 0px 0px",color:a,width:B,"min-height":"100%",position:ax,height:B},isMaterial:c,id:aw,needTheme:c,hasEditor:c,packed:c,events:[],child:[{readmeUrl:"https:",stack:c,visible:b,customStyle:a,childLimit:k,label:"路径推荐",type:"iwencai\u002FrecommendList",leaf:b,version:"1.12.0",animate:[],url:I,componentUuid:aq,script:[{name:ay,id:20240320,content:"return {\r\n  created: function created() {\r\n    this.isActive = !Boolean(this.$parent.$parent.$parent.$parent.$parent.$parent.question);\r\n    var showId ='tkPanel_bottomTag';\r\n  this.buryPointId = showId;\r\n  }\r\n};"}],props:{recommendList:[],isTransparent:b,renderType:"blue"},path:I,meta:{custom_editor_url:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0editor.js",js_url:I},style:{"background-color":a,margin:"-12px 0px -12px 0px",color:a,display:"block",width:B,position:ax,height:B},isMaterial:b,_id:19,id:ay,hasEditor:b,packed:c,events:[],isSetDefaultValue:b}]}},page:{layout:{layout_data:"[{\"uuid\":\"ztxxx06c0a024223920bbbeb1e0926\",\"showType\":\"lowcode\",\"children\":[]}]"},render_for:az,voice_txt:a,tracking_info:{},uuid:H},order:{is_auto:c,render_for:az,chart_type:"command",puuid:H}},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"suggest\u002Finputs",section:{id:10000,info_texts:[],show_type:"choice",choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{}},{answer_path:"logs\u002Ftrace_debug",section:{id:1005,info_texts:[],show_type:A,choice:[],result_page:{},tag_info_list:[],is_last:b},logs:[],extra:{action_name:F,with_paid_index:c,no_refresh_answer:c,answer_source:{agent_id:a,agent_name:a,execute_mode:C,answer_chain_name:X},is_deep_research:c,deep_thinking:c,create_time:1743914408943},is_last:b}],questionItem:{data:{qStr:h,encodeFlag:c,imageData:o,docsData:[],quoteData:o},tplType:"question"},events:aA,agentId:a,param:{entity_info:{},add_info:{ori_question:h},event_list:aA,client_ip:a,question:h,user_id:z,user_name:a,trace_id:i,session_id:i,source:n,input_type:_}}],userId:z,userName:a,startTime:$,mobileType:a,comeFrom:a,textConstants:{},dialogContainer:o,endSignal:c,theme:"white",showTracePopup:c,traceListData:[],chatTraceTargetIndex:k,traceTableData:o,showMask:c}},serverRendered:b,routePath:"\u002Faime\u002Fshare\u002Fcaused-entas-q4-2024-eps-fall-forecasts-9de1ac\u002F",config:{_app:{basePath:aB,assetsPath:aB,cdnURL:"\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Fiwc-aime-seo\u002F"}}}}("",true,false,"progress\u002Fsearching_for",1000,"searching_for","other\u002FopenAnswer","What caused ENTA's Q4 2024 EPS to fall below forecasts?","b04f86f8-c95b-411d-b349-4424c2fc07b7","thinking",0,"rich_text","llm_generated","ths_ainvest_lite_web",null,"The user wants to analyze why ENTA's 2024Q4 EPS fell below expectation. I should focus on ENTA's latest report, earnings release date, analyst opinions, and reasons for missing expectations. I will use FinQuery to obtain such information; use Search for more detail depending on collected positive information.","Searching Web",2001,"📈 What were ENTA's key revenue sources in Q4 2024?","⚠️ What are the potential risks facing ENTA's business in the near term?","📊 How did ENTA's operating expenses change in Q4 2024 compared to forecasts?","STR","oeqxkhszf","oeqxkhszf_layer","base","dp22430709","signal","auto","agent","36062c2c26c44b02","fdd88203c9d5870a","explain news events",999,"39196","\u002F\u002Fcdn.ainvest.com\u002FfrontResources\u002Fs\u002Ffoiegras\u002FrecommendList\u002F1.12.0\u002FrecommendList@1.12.0index.js","Enanta Pharmaceuticals' Q4 2024 EPS fell below forecasts due to several factors:\n\n1. **Revenue Miss**: Enanta reported a revenue of $14.6 million for Q4 2024, which missed the estimates. This decline in revenue could contribute to the lower-than-expected EPS.\n2. **Increased Losses**: The company reported a net loss of $28.8 million for the quarter, which translates to a loss of $1.36 per share. This indicates a significant financial strain that could impact the EPS negatively.\n3. **Non-Recurring Items**: The quarterly report adjustments for non-recurring items suggest that there may have been one-time expenses or deductions that affected the net income and, consequently, the EPS.\n\nIn summary, Enanta's Q4 2024 EPS fell below forecasts due to a combination of revenue missing expectations, increased losses, and the impact of non-recurring items.","search",17,"Enanta Pharmaceuticals Inc Reports Q4 Loss of $1.36 Per Share, Revenue at $14.6 Million, Missing Estimates","These developments are crucial as they position Enanta as a leader in the RSV treatment landscape, offering potential first-in-disease and best-in-class treatments. Key Financial Metrics Enanta Pharmaceuticals Inc reported a net loss of $28.8 million for the fourth quarter, equating to a loss of $1....","https:\u002F\u002Fwww.gurufocus.com\u002Fnews\u002F2615403\u002Fenanta-pharmaceuticals-inc-reports-q4-loss-of-136-per-share-revenue-at-146-million-missing-estimates","2024-11-24","36062c2c26c44b02_1",12,"Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates","Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.36 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.33 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -1...","https:\u002F\u002Ffinance.yahoo.com\u002Fnews\u002Fenanta-pharmaceuticals-enta-reports-q4-221004778.html","2024-11-25","fdd88203c9d5870a_0","agent_common_v2\nagent-summary","normal_agent","NONE","typewrite",1743914384325,"stock","185","Querying Stock","I have obtained that ENTA's 2024Q4's earnings per share fell below expectation may be related to the revenue of US$68m and a statutory loss per share. Now I will use Search to investigate the reasons about the revenue of US$68m and the statutory loss per share.","Enanta Pharmaceuticals' Q4 2024 EPS fell below forecasts due to several factors:\n\n1","Enanta",". **Revenue Miss**: Enanta reported a revenue of $14.6 million for Q4 2024, which missed the estimates[^17]",2000,"normal",". This decline in revenue could contribute to the lower-than-expected EPS.\n2. **Increased Losses**: The company reported a net loss of $28.8 million for the quarter, which translates to a loss of $1.36 per share[^17]. This indicates a significant financial strain that could impact the EPS negatively.\n3. **Non-Recurring Items**: The quarterly report adjustments for non-recurring items suggest that there may have been one-time expenses or deductions that affected the net income and, consequently, the EPS[^12]",".\n\nIn summary, Enanta's Q4 2024 EPS fell below forecasts due to a combination of revenue missing expectations, increased losses, and the impact of non-recurring items.","2+707_496_21_554+0+0+b04f86f8-c95b-411d-b349-4424c2fc07b7+54888ad23cc76ba265337f5b37c04dd5+llm_generated+aimeTagAnalysis+0+0.06961224973201752+1","2+707_496_21_554+0+0+b04f86f8-c95b-411d-b349-4424c2fc07b7+4a78a47284bd7b427966838edc12319b+llm_generated+aimeTagAnalysis+0+0.05934542790055275+2","2+707_496_21_554+0+0+b04f86f8-c95b-411d-b349-4424c2fc07b7+20e41621b0f612e0a5fc92de9caab015+llm_generated+aimeTagAnalysis+0+0.03145083785057068+3",3,"recommend_query_list","ztxxx06c0a024223920bbbeb1e0926","send_text","item_type","rec_info","display_text","rec_reason","root","relative","iwencai\u002FrecommendList0326","aigc",Array(0),"\u002F"));</script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/b929a16.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/28ccbec.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/d9802b5.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/2077034.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/1e0f8d6.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/7a5f495.js" defer=""></script><script src="//cdn.ainvest.com/frontResources/s/iwc-aime-seo/921844b.js" defer=""></script>